Titre :

Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator''s choice in relapsed or refractory mantle cell lymphoma

Auteur(s) :

Arcaini, Luca [Auteur]

Lamy, Thierry [Auteur]
Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
Walewski, Jan [Auteur]
Medical University of Warsaw - Poland
Belada, David [Auteur]
University of Hradec Králové
Mayer, Jiri [Auteur]
University Hospital Brno
Radford, John [Auteur]
University of Manchester [Manchester]
Jurczak, Wojciech [Auteur]

Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Alexeeva, Julia [Auteur]
Saint Petersburg University [SPBU]
Rule, Simon [Auteur]
Plymouth University
Cabecadas, Jose [Auteur]
Centro Hospitalar de Lisboa Central E.P.E
Campo, Elias [Auteur]
Institut d'Investigacions Biomèdiques August Pi i Sunyer [IDIBAPS]
Pileri Stefano, A [Auteur]
Medical Oncology Unit, Dept of Medical Oncology and Hematology [Fondazione IRCCS Istituto Nazionale Tumori, Milan]
Biyukov, Tsvetan [Auteur]
Celgene Corporation
Patturajan, Meera [Auteur]
Celgene Corporation
Casadebaig Bravo, Marie-Laure [Auteur]
Celgene Corporation
Trneny, Marek [Auteur]

Titre de la revue :

British journal of haematology

Nom court de la revue :

Br. J. Haematol.

Numéro :

180

Pagination :

224-235

Date de publication :

2018

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

In the mantle cell lymphoma (MCL)-002 study, lenalidomide demonstrated significantly improved median progression-free survival (PFS) compared with investigator's choice (IC) in patients with relapsed/refractory MCL. Here ...
Lire la suite >In the mantle cell lymphoma (MCL)-002 study, lenalidomide demonstrated significantly improved median progression-free survival (PFS) compared with investigator's choice (IC) in patients with relapsed/refractory MCL. Here we present the long-term follow-up data and results of preplanned subgroup exploratory analyses from MCL-002 to evaluate the potential impact of demographic factors, baseline clinical characteristics and prior therapies on PFS. In MCL-002, patients with relapsed/refractory MCL were randomized 2:1 to receive lenalidomide (25 mg/day orally on days 1-21; 28-day cycles) or single-agent IC therapy (rituximab, gemcitabine, fludarabine, chlorambucil or cytarabine). The intent-to-treat population comprised 254 patients (lenalidomide, n = 170; IC, n = 84). Subgroup analyses of PFS favoured lenalidomide over IC across most characteristics, including risk factors, such as high MCL International Prognostic Index score, age ≥65 years, high lactate dehydrogenase (LDH), stage III/IV disease, high tumour burden, and refractoriness to last prior therapy. By multivariate Cox regression analysis, factors associated with significantly longer PFS (other than lenalidomide treatment) included normal LDH levels (P < 0·001), nonbulky disease (P = 0·045), <3 prior antilymphoma treatments (P = 0·005), and ≥6 months since last prior treatment (P = 0·032). Overall, lenalidomide improved PFS versus single-agent IC therapy in patients with relapsed/refractory MCL, irrespective of many demographic factors, disease characteristics and prior treatment history.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Équipe(s) de recherche :

Innovation/évaluation des médicaments injectables

Date de dépôt :

2019-02-26T17:07:01Z
2021-04-12T13:12:36Z